Ozempic, Mounjaro, or Wegovy: Which One Is Actually Right for You?
By JustGetWise · Updated October 2026 · How this site is researched · Not medical advice
Four GLP-1 drugs, same basic mechanism, but different molecules, doses and approvals. Here is what the published trial data and FDA approvals say, to help you understand which one fits your situation.
Quick answer
Mounjaro and Zepbound (tirzepatide) produce the highest average weight loss in trials: around 20–22% of body weight, versus 14.9% for semaglutide (Ozempic, Wegovy). But averages don't predict individual response, and insurance coverage often decides which one you can actually get. The right choice depends on your diagnosis, your insurance, and how your body responds.
Choose based on your situation
- If your primary goal is type 2 diabetes management: Ozempic (best insurance coverage) or Mounjaro (highest weight-loss upside if approved).
- If your primary goal is weight loss without diabetes: Zepbound (highest average results) or Wegovy (if Zepbound isn't covered).
- If you've already tried semaglutide (Ozempic or Wegovy) without results: ask about switching to tirzepatide. It has different receptor targets, and response can differ.
- If cost is the deciding factor: compare manufacturer savings cards, telehealth pricing, and pharmacy discount programs; see the full cost breakdown.
Trial data: SURMOUNT-1 (tirzepatide) showed 20–22% average body weight loss at the highest dose over 72 weeks. STEP-1 (semaglutide) showed 14.9% average over 68 weeks.
This article is for informational purposes only. It is not medical advice and should not replace a conversation with your doctor or prescriber. GLP-1 medications require a prescription and are not appropriate for everyone. Always consult a licensed healthcare provider before starting, stopping, or switching any medication.
Ozempic, Wegovy, Mounjaro and Zepbound share a mechanism, but they differ in molecule, dose and FDA approval. People who are switched from one to another by their insurer often report that the new drug does not work the same way for them.
There are now four major GLP-1 medications prescribed for weight loss and blood sugar control in the United States: Ozempic, Wegovy, Mounjaro, and Zepbound. They share a mechanism but they are not the same drug, and your body may respond to them very differently. Here is what the clinical data and the FDA approvals actually say about each one.
How to Read This Comparison
The Four Drugs at a Glance
This comparison draws on the published STEP (semaglutide) and SURMOUNT (tirzepatide) trials, FDA prescribing information, and manufacturer pricing pages, all linked under Sources. Here is what each drug actually is.
Ozempic (semaglutide, Novo Nordisk)
FDA-approved for type 2 diabetes management. Weekly injection, max dose 2mg. Widely prescribed off-label for weight loss. The most commonly covered by insurance among the four, which is why many patients start here even when weight loss is their primary goal.
Wegovy (semaglutide, Novo Nordisk)
FDA-approved specifically for chronic weight management (2021) and cardiovascular risk reduction (2024). Same active ingredient as Ozempic but a different max dose: 2.4mg weekly vs 2mg. The higher dose matters, and emerging research suggests the formulation differences may matter too.
Mounjaro (tirzepatide, Eli Lilly)
FDA-approved for type 2 diabetes (2022). Dual mechanism: targets both GLP-1 and GIP receptors simultaneously, which is a meaningful pharmacological difference from semaglutide. Max dose 15mg weekly. Clinical trials showed average weight loss of 20–22% of body weight, which is significantly higher than semaglutide trials.
Zepbound (tirzepatide, Eli Lilly)
The weight-loss-approved version of Mounjaro (2023), also approved for obstructive sleep apnea in 2024. Same tirzepatide molecule, same max dose of 15mg. If your primary goal is weight loss and you don't have a type 2 diabetes diagnosis, this is the version your prescriber will reach for.
The Mechanism Difference That Actually Matters
All four drugs work by mimicking hormones that regulate blood sugar and appetite. But they don't all mimic the same hormones. Ozempic and Wegovy target one receptor: GLP-1. Mounjaro and Zepbound target two: GLP-1 and GIP simultaneously.
GIP (glucose-dependent insulinotropic polypeptide) plays a role in fat metabolism and insulin secretion that GLP-1 alone doesn't fully address. Activating both receptors appears to produce stronger appetite suppression and greater fat loss for many people, which is reflected in the trial data. This isn't a marketing distinction. It's a real pharmacological difference that helps explain why patients who've tried both classes often report very different experiences.
Worth knowing
Some people who struggle on semaglutide (Ozempic or Wegovy) and later switch to tirzepatide (Mounjaro or Zepbound) report stronger appetite suppression and better results, and some report the reverse. Individual response to each receptor class varies. There is no way to predict which will work better for a given person before trying it.
What the Clinical Trials Actually Show, and What They Don't
The headline numbers from the major trials are real: Wegovy's STEP 1 trial showed an average of about 15% body weight loss over 68 weeks. The SURMOUNT-1 trial for Zepbound showed an average of around 20–22%. On paper, tirzepatide wins.
But those are averages across large populations. The distribution underneath is wide. Some participants in these trials lost 30% or more of their body weight. Others lost almost nothing despite completing the full titration and following protocol. Scientists don't fully understand why yet. Genetics, hormonal status, and other patient characteristics are under active investigation. The average cannot tell you how you personally will respond.
Why the Same Drug Works Differently for Different People
GLP-1 medications don't work in isolation. Your hormonal environment, existing conditions, and other medications you take all affect how well they work. Several factors commonly appear in clinical reports as reasons why results diverge.
Menopause significantly affects metabolism and insulin sensitivity, which can blunt the drug's effect for some postmenopausal patients. Hypothyroidism and Hashimoto's disease can reduce metabolic rate independently of the GLP-1 mechanism. Corticosteroid use is specifically documented as counteracting the effects of GLP-1 drugs. And body weight itself may play a role: there is evidence that starting doses may be effectively lower relative to body weight in patients with higher starting body mass, which could explain slower early results.
Worth knowing
If you are on a regular steroid prescription (including inhaled corticosteroids for asthma), tell your prescriber before starting a GLP-1. The interaction is not dangerous, but it may meaningfully reduce how well the medication works and set unrealistic expectations about your results.
Side Effects: Where the Experience Genuinely Diverges
Nausea, vomiting, constipation, and fatigue are documented across all four drugs, particularly during the early titration phase. But the frequency, severity, and character of side effects differ between semaglutide and tirzepatide, and even between Ozempic and Wegovy, despite sharing an active ingredient.
In publicly shared patient reports, Zepbound and Mounjaro more commonly produce fatigue after injection (often described as occurring about 8 hours post-dose) but tend to produce less intense nausea than semaglutide for some people. Wegovy at 2.4mg, the highest available semaglutide dose, carries a higher reported incidence of GI symptoms than Ozempic at 2mg, which aligns with a dose-dependent effect. Some patients tolerate one drug in a class but not the other, even when the active ingredient is the same.
Realistic Timeline: What Actually Happens Month by Month
Treatment on GLP-1 medications tends to follow a fairly consistent pattern of phases, even though the exact numbers vary widely. Understanding what tends to happen when can prevent you from quitting during a temporary side-effect peak or panicking about a plateau that's actually normal.
Most prescribers titrate doses upward across the first 16 to 20 weeks. Side effects are usually heaviest during dose increases, not at steady state. Weight loss in the first month is often minimal because the dose is still subclinical. The real curve doesn't start until you reach a therapeutic dose, which is usually month 3 or later.
| Phase | What typically happens | What to watch for |
|---|---|---|
| Month 1Starting dose | Appetite suppression begins within days. Weight loss usually 2-5 lbs, mostly water and reduced food intake. Side effects (nausea, constipation, fatigue) start within first week. | Don't expect dramatic results. The starting dose is intentionally low to build tolerance. Side effects at this dose are normal and usually fade. |
| Months 2-3First titrations | Weight loss accelerates to 1-2 lbs/week for many. Side effects spike at each dose increase, then settle. Food noise reduction becomes noticeable. | If side effects are unmanageable at a titration, ask your prescriber about staying at the current dose longer. There's no rush to maximum dose. |
| Months 4-6Therapeutic dose | Most patients reach steady-state results: 10-15% body weight loss by month 6 on semaglutide, 15-20% on tirzepatide. Side effects significantly diminish at maintenance dose for most. | First plateau often appears around month 4-5. This is normal. Don't panic-switch drugs. Plateaus typically resolve within 4-8 weeks if you maintain calorie deficit and protein intake. |
| Months 7-12Stabilization | Weight loss slows. Trial-data averages converge around month 12. Many patients reach their personal "set point" reduction here. Side effects are usually minimal. | This is where strength training and protein matter most. Up to 30% of weight lost on GLP-1s can be lean muscle. Lifting and eating 0.8-1g protein per pound of goal weight protects what you've built. |
| Year 2+Maintenance | Most patients maintain results while on medication. Discontinuation studies show 50-70% of weight typically returns within 12 months of stopping for those who don't adjust eating patterns. | Discuss long-term plan with prescriber early. Some patients taper to lower maintenance dose; others stay at therapeutic dose indefinitely. Both are legitimate strategies. |
If your timeline doesn't match this
The timeline above reflects what tends to happen for many patients. It is not what will definitely happen for you. Slower starters who lose 10 pounds at month 6 instead of 25 are still having a clinical response. Your prescriber can tell you whether your trajectory is concerning or just slower than average. Don't compare your numbers to anonymous online success stories that may be cherry-picked outliers.
The Insurance Maze: Why Forced Switches Are a Real Problem
Insurance coverage for GLP-1 medications is one of the most frustrating aspects of treatment. Ozempic is frequently covered because it has a diabetes approval. Wegovy, Mounjaro, and Zepbound have weight-loss approvals but coverage depends entirely on your plan, your employer, and sometimes whether your BMI or comorbidities meet specific thresholds.
Many patients who start on a drug that works for them are later forced to switch because their insurer changes its formulary, their employer changes plans, or their diagnosis code no longer qualifies. The common claim that these drugs are "practically identical" so switching doesn't matter does not match what many people report when they switch classes or even switch within the semaglutide class at different doses.
If your insurance forces a switch
Document your current results before switching. If your outcomes worsen significantly after a formulary-mandated switch, your prescriber can often file a medical necessity appeal, but they need clinical documentation of your previous response. Track weight, side effects, and subjective wellbeing consistently throughout treatment, not just at check-ins.
The Cost Reality Without Insurance
Without insurance coverage, all four drugs are expensive. List prices for a monthly supply run between roughly $900 and $1,350 depending on the drug and dose, though actual out-of-pocket costs vary based on pharmacy, manufacturer savings programs, and whether you use a telehealth platform.
Eli Lilly runs a direct savings program for Zepbound that can significantly reduce cost for eligible patients without insurance. Novo Nordisk has similar programs for Wegovy. Telehealth platforms that prescribe GLP-1 medications often negotiate different pricing. The lowest cost isn't always from the pharmacy you'd expect, and it changes frequently enough that checking multiple sources before filling a prescription is worth the time.
The 2026 compounding update
Until 2024, many patients accessed compounded versions of semaglutide and tirzepatide through telehealth pharmacies at a fraction of brand-name cost, sometimes as low as $100-200 per month. That changed when the FDA removed both drugs from its official shortage list (semaglutide in February 2025, tirzepatide in late 2024), legally requiring 503A and 503B compounding pharmacies to stop producing them.
As of 2026, the FDA has continued enforcement: warning letters, import refusals, and prosecution of unlicensed sellers. A handful of telehealth providers still offer "personalized" semaglutide formulations under 503A patient-specific exemptions, but these operate in a legally narrow space. Most legitimate telehealth providers have transitioned to brand-name fulfillment or to alternative compound peptide protocols. If a provider is offering compounded GLP-1s at $200/month with no individualized prescription justification, it's worth asking exactly how they're complying with current FDA guidance.
Approximate monthly costs (without insurance)
Ozempic
~$850–950
Wegovy
~$1,300–1,350
Mounjaro
~$950–1,050
Zepbound
~$550–1,000*
*Zepbound range reflects Eli Lilly's savings vial program, which offers significant discounts for patients paying out-of-pocket. Prices subject to change. Verify before filling.
How to Actually Get Prescribed in 2026: Doctor vs Telehealth
There are two realistic paths to a GLP-1 prescription in the US in 2026, and which one fits you depends mostly on your insurance situation, your relationship with a primary care doctor, and how patient you are with the process.
Both paths produce legitimate prescriptions for the same FDA-approved medications. The differences are speed, cost, level of medical follow-up, and which drug your prescriber will reach for first.
Path 1: Primary care doctor or endocrinologist
Best when: you have a strong relationship with a doctor, your insurance covers GLP-1s, or you have a T2D or qualifying obesity diagnosis.
- Most likely to result in insurance coverage if you qualify
- Comprehensive lab work and follow-up included as part of standard care
- Easier to manage co-existing conditions (thyroid, diabetes, cardiovascular)
- Slower: 2-6 weeks from first appointment to first injection, longer if appeals are needed
- If your doctor isn't familiar with the full GLP-1 range, you may be steered to Ozempic by default regardless of fit
Path 2: Telehealth provider
Best when: insurance doesn't cover GLP-1s, you don't have a specialist nearby, or your primary care doctor is unwilling or unfamiliar with the medications.
- Online intake quiz, video consultation, prescription typically issued within days
- Cash-pay model: monthly membership or program fees range from none (Refills) to $199 (Calibrate), with $79 at Mochi Health and $149 at Hims/Hers and Ro after a $39 first month; medication cost separate or bundled depending on provider
- Wider access to weight-loss-approved drugs (Wegovy, Zepbound) without the insurance friction
- Quality varies significantly: legitimate providers require labs, follow-ups, and have licensed prescribers; questionable ones skip those steps
- Providers worth evaluating: Hims/Hers, Ro, Found, Refills, Calibrate, and Mochi Health are among the larger established platforms. Compare on lab requirements, follow-up cadence, medication source, and cancellation terms before committing.
Red flags in any telehealth provider
No required lab work before prescribing, no follow-up appointments scheduled, vague answers about which pharmacy fills your prescription, prescriptions issued without a video or written consultation with a licensed prescriber, offers of compounded GLP-1s without explanation of the legal basis, or pressure to sign long-term contracts. Legitimate providers can answer all of these directly.
Who Each Drug Is Actually Designed For
FDA approvals determine which drug your prescriber is most likely to reach for based on your primary diagnosis. Insurance coverage often follows these approvals. Understanding the intent behind each drug's approval helps you understand what conversation to have with your doctor.
Ozempic: Type 2 diabetes with weight concerns
Primary approval is glycemic control. If you have a T2D diagnosis and want to lose weight, this is where most doctors and insurers will start. Widely available, widest insurance coverage.
Wegovy: Weight loss as the primary goal
The weight-loss approval means your prescriber can justify it for obesity or weight-related cardiovascular risk without a diabetes diagnosis. Highest semaglutide dose available. Insurance coverage is improving but still inconsistent.
Mounjaro: Type 2 diabetes, want stronger results than Ozempic
If you have T2D and Ozempic hasn't delivered enough, tirzepatide's dual mechanism is the clinically supported next step. Consistently shows better outcomes in head-to-head data. Coverage requires diabetes diagnosis.
Zepbound: Weight loss, want the strongest available option
The highest average weight loss in clinical trials of any approved medication in this class. Also FDA-approved for obstructive sleep apnea treatment in 2024. The right choice for weight loss when your insurer covers tirzepatide and you don't have a T2D diagnosis.
When to use one
The cleanest path is: start with what your insurance covers, document your response rigorously, and appeal or switch if the results are meaningfully poor. A prescriber experienced with GLP-1 medications can help you navigate the insurance documentation required to access a different drug if your first choice isn't working.
Also Worth Knowing
What Won't Help You, and What to Ignore
Online communities claiming these drugs are identical. They are not. Ozempic and Wegovy share an active ingredient but differ in dose and titration. Mounjaro and Zepbound use a different molecule entirely. Telling someone their body is wrong for responding differently is not helpful and not accurate.
Comparing your three-month results to someone else's. Trial data shows a wide range of outcomes. The person who lost 30 pounds in three months and the person who lost 4 pounds in three months may both be having a normal response for their body. Your trajectory is not a reflection of your effort or discipline.
Stopping because of early side effects before reaching maintenance dose. GI symptoms are most common during the early titration phase when doses are increasing. Many people report that side effects ease once they reach a stable maintenance dose. This is worth discussing with your doctor before stopping.
Expecting results without any change to eating behavior. These drugs suppress appetite and reduce food noise. They don't override the effect of a high-sugar diet. A high-sugar or high-calorie diet can blunt the results. The drug gives you a significant advantage; it does not do all the work.
Restricting calories to 1,000 per day or below. Some people on these medications severely restrict their calorie intake, either on advice or on their own. Research consistently shows that very low calorie intake causes muscle loss rather than fat loss and triggers metabolic adaptation. Most prescribers recommend no lower than 1,400–1,600 calories for adults, with higher targets for anyone active.
Full Comparison
All Four Drugs, Side by Side
A quick reference of the key differences between all four GLP-1 medications currently available in the US.
| Drug | Mechanism | Approved for | Avg weight loss | Est. monthly cost* |
|---|---|---|---|---|
| Ozempicsemaglutide | GLP-1 only | Type 2 diabetes | ~12–15% | ~$900 |
| Wegovysemaglutide | GLP-1 only | Weight loss, cardiovascular risk | ~15% | ~$1,350 |
| Mounjarotirzepatide | GLP-1 + GIP | Type 2 diabetes | ~20–22% | ~$1,000 |
| Zepboundtirzepatide | GLP-1 + GIP | Weight loss, sleep apnea | ~20–22% | ~$550–1,000 |
*Estimated list prices without insurance. Zepbound range reflects Eli Lilly's vial savings program. Prices change frequently. Verify with your pharmacy or telehealth provider. Average weight loss figures are from registration-trial data at highest approved doses; individual results vary significantly.
If This Isn't For You
When GLP-1 Isn't the Right Tool
GLP-1 medications are powerful for weight loss and blood sugar control, but they aren't the answer to every body-composition or wellness goal. A few situations where reaching for a GLP-1 either won't help or isn't the right starting point:
Your goal is muscle gain or anti-aging, not weight loss
GLP-1s suppress appetite, which makes hitting protein targets harder. For people whose main concern is recovery, energy, sleep quality, or age-related body composition shifts, peptide therapy options like sermorelin operate on a different mechanism: they stimulate the body's own growth hormone production rather than suppressing appetite. Mechanism, cost, and risk profile are all different from GLP-1s.
You have less than 15-20 pounds to lose
Trial data for GLP-1s comes from populations with significant obesity. The cost-benefit calculation for someone wanting to lose 10 pounds is different: structured lifestyle change, strength training, and sleep optimization produce comparable results without ongoing prescription cost or side effects. Many prescribers will decline to prescribe for cosmetic-range weight goals.
You have a history of pancreatitis, medullary thyroid cancer, or MEN-2
FDA prescribing information lists these as contraindications. This isn't a gray area: a different approach is medically required.
Your relationship with food is the underlying issue
GLP-1s reduce food noise and physical hunger, but they don't address emotional eating, binge cycles, or restrictive patterns. Without addressing the behavior, weight regain after stopping or a shift to other coping mechanisms is a common risk. A therapist or registered dietitian who specializes in disordered eating is often the right first step.
A different path: peptide therapy
If recovery, sleep, and energy are your goals more than weight loss, peptide therapy is the comparable conversation. Sermorelin and similar GHRH-analog peptides work by stimulating natural growth hormone release rather than mimicking gut hormones. The mechanism, cost, and patient experience differ meaningfully from GLP-1s.
The Bottom Line
The Right Drug Is the One That Works for Your Body
These four medications share a mechanism but they are not interchangeable. Your insurer may treat them as equivalent. Your pharmacist may tell you a switch shouldn't matter. The clinical data says otherwise: different molecules, different doses, and a wide spread of individual responses.
If you are on a drug that's working, document your results and fight to stay on it. If you are on a drug that isn't working, or that you were forced to switch to, that experience is information. Bring it to your doctor with specifics: weight changes, side effects, timing, how you felt before versus after. A prescriber with GLP-1 experience can help you navigate an appeal or a transition to something that actually fits your body.
Telehealth platforms have made access to these medications significantly easier for people who don't have a specialist nearby or whose primary care doctor is unfamiliar with the full range of options. If you haven't been able to have a nuanced conversation about which drug is right for you, a telehealth consultation is often a practical starting point.
If you're considering a GLP-1 medication, start by talking to your primary care doctor or an endocrinologist. They can evaluate your full health picture and discuss which option fits your situation.
Frequently Asked Questions
Is Ozempic or Mounjaro more effective for weight loss?
Clinical trial data shows Mounjaro (tirzepatide) produces greater average weight loss than Ozempic (semaglutide) at comparable doses. The SURMOUNT-1 trial showed tirzepatide achieving up to 22.5% body weight reduction at the highest dose, while the STEP trials showed semaglutide achieving up to 14.9%. However, individual results vary significantly based on genetics, starting weight, and metabolic factors. More weight loss on average does not mean it will work better for any specific person.
What is the difference between Ozempic and Wegovy?
Ozempic and Wegovy contain the same active ingredient, semaglutide, but are FDA-approved for different purposes. Ozempic is approved for type 2 diabetes management and comes in doses up to 2mg. Wegovy is approved specifically for chronic weight management and comes in a higher dose (2.4mg). Insurance coverage, cost, and availability differ significantly between them because of their different approved indications.
How much do Ozempic, Mounjaro, and Wegovy cost without insurance?
Without insurance, all three drugs cost between $900 and $1,300 per month at retail pharmacy prices in the US. Manufacturer savings cards can reduce this to $25 per month for eligible commercially insured patients, but these programs do not apply to Medicare or Medicaid. Compounded semaglutide from licensed pharmacies has been available at significantly lower prices, though the FDA has signaled increasing scrutiny of compounded versions as supply shortages resolve.
Which GLP-1 drug has the fewest side effects?
All GLP-1 drugs share a similar side effect profile dominated by nausea, vomiting, and gastrointestinal discomfort, particularly during dose escalation. Clinical trials do not show a consistent winner for tolerability across the class. Tirzepatide (Mounjaro and Zepbound) showed slightly higher rates of GI side effects in trials at higher doses, but this varied by individual. Starting at the lowest dose and escalating slowly is the most reliable way to reduce side effects regardless of which drug you use.
Can you switch from Ozempic to Mounjaro?
Yes, switching is medically possible and happens frequently when insurance coverage changes or when a prescriber wants to try a different mechanism. The transition typically involves stopping one drug, waiting for it to clear (usually a few weeks), and starting the other at a low dose. Some patients who plateau on semaglutide see renewed results after switching to tirzepatide. Any switch should be managed by a prescribing physician who can monitor the transition and adjust dosing appropriately.
Can you still get compounded semaglutide or tirzepatide in 2026?
The FDA removed both drugs from its official shortage list (tirzepatide in late 2024, semaglutide in February 2025), which legally required 503A and 503B compounding pharmacies to stop producing them. As of 2026, the FDA has continued enforcement through warning letters and import refusals. A handful of telehealth providers still offer "personalized" formulations under 503A patient-specific exemptions, but these operate in a legally narrow space. Most legitimate telehealth providers have transitioned to brand-name fulfillment, and the lowest-cost options are now Eli Lilly's direct Zepbound vial program and manufacturer savings cards for eligible patients.
How long does it take to see results on GLP-1 medications?
Appetite suppression usually begins within the first week, but meaningful weight loss typically starts around month 2 to 3 once the dose is titrated up. Trial-data averages of 10 to 15% on semaglutide and 15 to 20% on tirzepatide are usually reached by month 6 to 12. A first plateau around month 4 to 5 is normal and usually resolves within 4 to 8 weeks if you maintain calorie deficit and protein intake. If your trajectory is significantly below trial averages after reaching therapeutic dose, discuss with your prescriber.
Is telehealth a legitimate way to get a GLP-1 prescription?
Yes, when the provider uses licensed prescribers, requires baseline lab work, schedules follow-ups, and is transparent about which pharmacy fills your prescription. Established platforms like Hims/Hers, Ro, Found, Refills, Calibrate, and Mochi Health operate under these standards. Red flags include no required labs, no follow-up appointments, vague answers about pharmacy sourcing, and pressure to sign long-term contracts. Legitimate telehealth is often the most practical path when insurance does not cover GLP-1s or when your primary care doctor is unfamiliar with the full range of options.
Sources
- Wilding et al., Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1), New England Journal of Medicine, 2021: average weight loss of about 15 percent (14.9 percent) over 68 weeks on semaglutide 2.4 mg.
- Jastreboff et al., Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1), New England Journal of Medicine, 2022: average weight loss of up to about 21 percent at the highest tirzepatide dose over 72 weeks (about 22.5 percent among participants who stayed on treatment).
- Ozempic (semaglutide) prescribing information, Novo Nordisk: Ozempic's type 2 diabetes indication and its dosing schedule.
- Wegovy (semaglutide) prescribing information, DailyMed, U.S. National Library of Medicine: the 0.25 mg starting dose, four-week dose steps and 2.4 mg maintenance dose.
- Mounjaro (tirzepatide) prescribing information, Eli Lilly: Mounjaro's type 2 diabetes indication, 2.5 mg starting dose and 15 mg maximum dose.
- Zepbound (tirzepatide) prescribing information, DailyMed, U.S. National Library of Medicine: the 2.5 mg starting dose and 2.5 mg increases at least four weeks apart.
- FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize, U.S. Food and Drug Administration: the end of the semaglutide and tirzepatide shortages and the 503A and 503B rules compounders must now follow.
- FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, U.S. Food and Drug Administration: adverse event reports linked to dosing errors with compounded semaglutide and tirzepatide, and the risks of unapproved and counterfeit products.
- GLP-1s from $5/day, Refills: the starting price of $5 a day, the same price at every dose, no membership or app fees, and free shipping.
- Weight Loss Membership, Hims: the required membership, $39 for the first month and $149 a month after that.
- Ro Body pricing, Ro: Wegovy and Zepbound prices by dose and the Ro Body membership fee.
- Mochi Health: the monthly membership fee.
- Pricing, Calibrate: the $199 monthly program fee and the 3-month commitment.
Drug prices on this page are list and program prices as published by manufacturers and pharmacies in June 2026 and have not been re-checked since; telehealth membership and program fees were checked on each program's own website in October 2026. Confirm current prices with your pharmacy or provider.